
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and ...

Study design, patient eligibility and treatment This was a phase 1, first-in-human, open-label, nonrandomized, dose-escalation ...

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and ...

Study design, patient eligibility and treatment This was a phase 1, first-in-human, open-label, nonrandomized, dose-escalation ...